雷洛昔芬有哪几个版本?分别多少钱?

Raloxifene is a drug used to treat and prevent postmenopausal osteoporosis and also reduces the incidence of invasive breast cancer in high-risk women. Currently, there are two main versions on the market: generic drugs produced by Nippon Eiko Co., Ltd. and original drugs produced by Eli Lilly and Company of the United States. In addition, raloxifene has been launched in China and entered into medical insurance, providing patients with more choices. This article will introduce in detail the version and price of raloxifene as well as its listing and medical insurance situation in China.

What are the versions of raloxifene?

There are two main versions worldwide, each produced by different pharmaceutical companies. The two versions are identical in ingredients and specifications, but differ in price and branding.

Nikko Co., Ltd. version

Nikko Co., Ltd. is a well-known pharmaceutical company in Japan. The generic raloxifene produced by Nipponko Co., Ltd. occupies a certain share of the market. Its specification is 60mg*100 tablets/box, the price is relatively low, and it is suitable for patients with limited budget.

Eli Lilly Company of the United States version

Eli Lilly Company of the United States is the original manufacturer of raloxifene, with the trade name Evista. As the first SERM drug approved for the treatment of postmenopausal osteoporosis, Lilly's version of raloxifene has a high degree of recognition in terms of quality and efficacy.

Whether it is the generic drug of Nippon Medical Industry Co., Ltd. or the original drug of Eli Lilly, both are 60mg tablets, and patients can choose the appropriate version according to their own needs.

How much do different versions of raloxifene cost?

There is a significant price difference between the two versions of raloxifene, which is mainly affected by brand, production cost and market positioning.

Price of Nippon Medical Industry Co., Ltd. version

The generic version of raloxifene produced by Nippon Medical Industry Co., Ltd. has a specification of 60mg*100 tablets/box and a price of about US$42 per box. The price is relatively affordable and suitable for patients taking medication for a long time.

Price of the American Eli Lilly and Company version

The original drug Evista produced by Eli Lilly and Company has the same specification of 60mg*100 tablets/box, and the price is about US$70 per box. Because it is an original drug, its price is higher, but its quality and efficacy have been widely recognized.

Patients can choose a suitable version based on their own financial conditions and medication needs. Generic drugs have more advantages in price, while original drugs are better in brand and trust.

The listing and medical insurance status of raloxifene in China

Raloxifene has been launched in China and has been included in the medical insurance catalog, providing more convenience for domestic patients.

Marketing status in China

Raloxifene has been approved for marketing by the Chinese Food and Drug Administration, and generic drugs are currently available on the market. Indications include the treatment and prevention of postmenopausal osteoporosis and the reduction of invasive breast cancer in high-risk women.

Medical insurance coverage

Raloxifene has been included in China’s medical insurance catalog, and patients can reimburse part of the cost through medical insurance to reduce their financial burden. The coverage of medical insurance policies further improves the accessibility of medicines.

The launch and medical insurance coverage of raloxifene in China provide more treatment options for postmenopausal female osteoporosis patients and also reduce medication costs.